Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy,
pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in
combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in
subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received
prior therapy. The goal of the Expansion phase of the study is to evaluate the safety,
efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with
palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced
or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.